PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Bernhardt, D.* ; Grosu, A.L.* ; Rieken, S.* ; Krieg, S.M.* ; Wick, W.* ; Wiestler, B.* ; Schmidt-Graf, F.* ; Sahm, F.* ; Gempt, J.* ; Meyer, B.* ; Krause, B.J.* ; Petersen, C.* ; Fietkau, R.* ; Thomas, M.A.* ; Giordano, F.A.* ; Wittig-Sauerwein, A.* ; Tabatabai, G.* ; Hau, P.* ; Steinbach, J.* ; Combs, S.E.

DEGRO practical guideline for central nervous system radiation necrosis part 2: Treatment.

Strahlenther. Onkol. 198, 971-980 (2022)
Verlagsversion DOI PMC
Open Access Hybrid
Creative Commons Lizenzvertrag
PURPOSE: The Working Group for Neurooncology of the German Society for Radiation Oncology (DEGRO; AG NRO) in cooperation with members of the Neurooncological Working Group of the German Cancer Society (DKG-NOA) aimed to define a practical guideline for the diagnosis and treatment of radiation-induced necrosis (RN) of the central nervous system (CNS). METHODS: Panel members of the DEGRO working group invited experts, participated in a series of conferences, supplemented their clinical experience, performed a literature review, and formulated recommendations for medical treatment of RN, including bevacizumab, in clinical routine. CONCLUSION: Diagnosis and treatment of RN requires multidisciplinary structures of care and defined processes. Diagnosis has to be made on an interdisciplinary level with the joint knowledge of a neuroradiologist, radiation oncologist, neurosurgeon, neuropathologist, and neurooncologist. If the diagnosis of blood-brain barrier disruptions (BBD) or RN is likely, treatment should be initiated depending on the symptoms, location, and dynamic of the lesion. Multiple treatment options are available (such as observation, surgery, steroids, and bevacizumab) and the optimal approach should be discussed in an interdisciplinary setting. In this practice guideline, we offer detailed treatment strategies for various scenarios.
Impact Factor
Scopus SNIP
Altmetric
4.033
0.000
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Schlagwörter Bevacizumab ; Blood–brain Barrier Disruptions ; Brain Metastases ; Glioma ; Radiation Necrosis ; Stereotactic Radiotherapy ; Steroids
Sprache englisch
Veröffentlichungsjahr 2022
HGF-Berichtsjahr 2022
ISSN (print) / ISBN 0179-7158
e-ISSN 1439-099X
Zeitschrift Strahlentherapie und Onkologie : Journal of Radiation Oncology, Biology, Physics
Quellenangaben Band: 198, Heft: 11, Seiten: 971-980 Artikelnummer: , Supplement: ,
Verlag Urban & Vogel
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Radiation Medicine (IRM)
POF Topic(s) 30203 - Molecular Targets and Therapies
Forschungsfeld(er) Radiation Sciences
PSP-Element(e) G-501300-001
DOI 10.1007/s00066-022-01973-8
WOS ID WOS:000847245800002
Scopus ID 85137293390
PubMed ID 36038670
Erfassungsdatum 2022-11-14
[➜Korrektur melden]